Mandala coloring to reduce anxiety and fear in children with leukemia before intrathecal chemotherapy
Official title: The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment
Run by Ege University · NCT07203742 · Data updated 2026-11-12
This will try mandala coloring with children aged 4–12 who have leukemia to see if it lowers their anxiety and fear before intrathecal chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 4 Years to 12 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Ege University Academic / other |
| Drugs / interventions | chemotherapy, methotrexate |
| Locations | 1 site (Izmir) |
| Status | Recruiting |
| Started | September 29, 2025 |
| Main results expected | August 2026 |
| Study ends | September 2026 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT07203742 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 4–12 with leukemia who are hospitalized and receiving intrathecal chemotherapy at the Pediatric Hematology Clinic and whose caregiver is a Turkish-speaking volunteer meet the typical inclusion criteria.
✕Probably not a fit
Children outside the 4–12 age range, those with other chronic illnesses or systemic infections, those with documented chemotherapy-related psychiatric diagnoses, or children unable to engage with coloring activities may not receive benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Children with leukemia hospitalized at Ege University will complete a mandala coloring activity immediately before their scheduled intrathecal chemotherapy, and demographic information will be recorded. Anxiety and fear will be measured using validated anxiety and fear scales before and after the intervention. The intervention is non-pharmacological and delivered in the Pediatric Hematology Clinic setting by nursing staff. Results will compare pre-procedure anxiety and fear levels to determine the effect of the mandala activity.
Why it matters
Potential benefit: If successful, mandala coloring could lower pre-procedure anxiety and fear in children undergoing intrathecal chemotherapy, improving comfort and cooperation during the procedure.
How similar studies have gone: Prior small studies of art therapy and distraction techniques have shown modest reductions in procedure-related anxiety, and mandala coloring has shown promising but limited evidence in pediatric and adult settings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patient must be between 4 and 12 years of age. * The patient must be hospitalized and followed up at the Pediatric Hematology Clinic. * The patient must only be receiving leukemia treatment. * The patient must not have any other chronic diseases. * The patient must not have any systemic infections. * The patient has received at least two courses of intrathecal chemotherapy treatment * The patient does not have a diagnosis of psychological/mental symptoms as a side effect of chemotherapy treatment * Intrathecal treatment will be administered to the patient in accordance with the chemotherapy protocol * The patient and the caregiver parent are volunteers * The caregiver parent speaks Turkish and is open to communication. Exclusion Criteria: * Cases that do not meet the inclusion criteria will be excluded from the study.
Where it's running
-
Ege University Childrens Hospital
Izmir, Turkey (Türkiye) Recruiting
Study contacts
- Principal investigator: Seda Ardahan Sevgili, Ph.D. — Ege University
- Study coordinator: Seda ARDAHAN SEVGİLİ, Ph.D
- Email: sedardahan@gmail.com
- Phone: 00902323115572
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using revumenib to treat acute leukemia after stem cell transplant
This study is testing a new drug called revumenib to see if it can help people with acute leukemia feel better after they’ve had a stem cell transplant.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Observatory of adults with Ph+ ALL receiving BCR-ABL1 inhibitors with chemotherapy, steroids, or monoclonal antibodies
This study follows adults with Philadelphia-positive acute lymphoblastic leukemia who are being treated with a combination of BCR-ABL1 inhibitors and other therapies to see how they fare in real-world practice.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
FXS0683 in relapsed or refractory blood cancers
This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.
-
CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers
This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.